NCALD as a potential predictive biomarker for the efficacy of platinum-based - Supplementary Table 1

Aim: Since reliable response predictors to platinum-based chemotherapy in ovarian cancer (OC) are scarce,
we characterize NCALD as a predictive biomarker. Materials & methods: NCALD mRNA (n = 100) and
protein (n = 102) expression was analyzed in OC samples and associated with patient outcome. A stable
OC cell line knockdown was generated and cellular response to platinum was explored. Results: High
NCALD mRNA and protein expression was significantly associated with longer overall patient survival
(p = 0.037/0.002). Knockdown experiments revealed a significant association between cisplatin sensitivity
and NCALD expression. Conclusion: Low NCALD expression was associated with reduced sensitivity to
platinum-based chemotherapy. NCALD may be a new biomarker candidate to identify patients whomight
benefit from platinum-based chemotherapy.